Ayalew Tefferi

102.8k total citations · 15 hit papers
1.1k papers, 54.7k citations indexed

About

Ayalew Tefferi is a scholar working on Genetics, Hematology and Molecular Biology. According to data from OpenAlex, Ayalew Tefferi has authored 1.1k papers receiving a total of 54.7k indexed citations (citations by other indexed papers that have themselves been cited), including 860 papers in Genetics, 783 papers in Hematology and 301 papers in Molecular Biology. Recurrent topics in Ayalew Tefferi's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (753 papers), Acute Myeloid Leukemia Research (475 papers) and Chronic Myeloid Leukemia Treatments (338 papers). Ayalew Tefferi is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (753 papers), Acute Myeloid Leukemia Research (475 papers) and Chronic Myeloid Leukemia Treatments (338 papers). Ayalew Tefferi collaborates with scholars based in United States, Italy and Germany. Ayalew Tefferi's co-authors include Animesh Pardanani, Terra L. Lasho, Ruben A. Mesa, Curtis A. Hanson, Christy M. Finke, Naseema Gangat, Mrinal M. Patnaik, Alessandro M. Vannucchi, Rhett P. Ketterling and James W. Vardiman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Ayalew Tefferi

1.1k papers receiving 53.6k citations

Hit Papers

The 2008 revision of the World Health Organization (WHO) ... 2000 2026 2008 2017 2009 2010 2008 2006 2007 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    2009 3.0k citations James W. Vardiman, Jüergen Thiele et al. Blood profile →
  2. Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
    2010 847 citations Srđan Verstovšek, Ruben A. Mesa et al. profile →
  3. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
    2008 830 citations Francisco Cervantes, Francesco Passamonti et al. Blood profile →
  4. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
    2006 758 citations Animesh Pardanani, Terra L. Lasho et al. Blood profile →
  5. Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms
    2007 669 citations Ayalew Tefferi et al. Leukemia profile →
  6. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
    2010 657 citations Naseema Gangat, Domenica Caramazza et al. Journal of Clinical Oncology profile →
  7. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
    2009 623 citations Francesco Passamonti, Francisco Cervantes et al. Blood profile →
  8. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    2007 604 citations Ayalew Tefferi, Jüergen Thiele et al. Blood profile →
  9. Myelofibrosis with Myeloid Metaplasia
    2000 547 citations Ayalew Tefferi profile →
  10. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
    2014 493 citations Ayalew Tefferi, Paola Guglielmelli et al. Blood profile →
  11. Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
    2011 435 citations Ayalew Tefferi, Rakhee Vaidya et al. Journal of Clinical Oncology profile →
  12. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
    2018 383 citations Tiziano Barbui, Jürgen Thiele et al. Blood Cancer Journal profile →
  13. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
    2014 366 citations Ayalew Tefferi, Terra L. Lasho et al. Leukemia profile →
  14. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
    2015 340 citations Animesh Pardanani, Claire Harrison et al. profile →
  15. Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
    2023 100 citations Ayalew Tefferi American Journal of Hematology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ayalew Tefferi United States 115 38.2k 34.8k 22.2k 15.9k 5.9k 1.1k 54.7k
Moshe Talpaz United States 98 22.8k 0.6× 29.2k 0.8× 11.0k 0.5× 13.1k 0.8× 4.6k 0.8× 778 44.8k
Francis J. Giles United States 105 15.8k 0.4× 20.4k 0.6× 15.0k 0.7× 6.3k 0.4× 4.6k 0.8× 786 41.9k
Andreas Hochhaus Germany 87 24.0k 0.6× 30.1k 0.9× 6.1k 0.3× 15.6k 1.0× 1.9k 0.3× 839 40.0k
Tiziano Barbui Italy 92 16.6k 0.4× 17.8k 0.5× 11.2k 0.5× 10.9k 0.7× 3.0k 0.5× 551 30.4k
Srđan Verstovšek United States 84 18.7k 0.5× 18.6k 0.5× 12.1k 0.5× 8.5k 0.5× 2.6k 0.4× 1.1k 30.0k
Jörge E. Cortes United States 139 41.4k 1.1× 60.4k 1.7× 23.6k 1.1× 19.7k 1.2× 6.4k 1.1× 2.3k 85.0k
Guillermo Garcia‐Manero United States 106 14.7k 0.4× 30.6k 0.9× 17.8k 0.8× 4.4k 0.3× 3.9k 0.7× 1.5k 44.1k
Michele Baccarani Italy 80 14.6k 0.4× 20.3k 0.6× 4.9k 0.2× 8.1k 0.5× 3.1k 0.5× 711 29.1k
John M. Goldman United Kingdom 83 14.3k 0.4× 22.2k 0.6× 5.1k 0.2× 8.6k 0.5× 4.0k 0.7× 496 29.8k
Susan O’Brien United States 100 17.3k 0.5× 21.3k 0.6× 8.3k 0.4× 5.6k 0.4× 5.0k 0.9× 840 36.5k

Countries citing papers authored by Ayalew Tefferi

Since Specialization
Citations

This map shows the geographic impact of Ayalew Tefferi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ayalew Tefferi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ayalew Tefferi more than expected).

Fields of papers citing papers by Ayalew Tefferi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ayalew Tefferi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ayalew Tefferi. The network helps show where Ayalew Tefferi may publish in the future.

Co-authorship network of co-authors of Ayalew Tefferi

This figure shows the co-authorship network connecting the top 25 collaborators of Ayalew Tefferi. A scholar is included among the top collaborators of Ayalew Tefferi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ayalew Tefferi. Ayalew Tefferi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
He, Rong, Abhishek A. Mangaonkar, Kebede H. Begna, et al.. (2025). Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases. Blood Cancer Journal. 15(1). 28–28. 1 indexed citations
2.
Gangat, Naseema, Natasha Szuber, & Ayalew Tefferi. (2025). JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management. American Journal of Hematology. 100(12). 2333–2354.
3.
Thiele, Jürgen, H. M. Kvasnicka, Umberto Gianelli, et al.. (2025). Evolution of WHO diagnostic criteria in “Classical Myeloproliferative Neoplasms” compared with the International Consensus Classification. Blood Cancer Journal. 15(1). 31–31. 2 indexed citations
4.
Tefferi, Ayalew, Naseema Gangat, Giuseppe Gaetano Loscocco, et al.. (2025). Essential Thrombocythemia. JAMA. 333(8). 701–701. 3 indexed citations
5.
He, Rong, Patricia T. Greipp, David S. Viswanatha, et al.. (2024). Molecular and clinical characterization of ETNK1-mutated myeloid neoplasms: the Mayo Clinic experience. Blood Advances. 8(18). 4807–4811. 2 indexed citations
6.
Csizmar, Clifford M., Mark E. Gurney, Rashmi Kanagal‐Shamanna, et al.. (2024). Prognostic Impact of the Number of TET2 Mutations in Myelodysplastic and Myeloproliferative Chronic Myelomonocytic Leukemia (CMML). Blood. 144(Supplement 1). 1820–1820. 1 indexed citations
7.
Tefferi, Ayalew, Aref Al‐Kali, Mrinal M. Patnaik, et al.. (2023). Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases. American Journal of Hematology. 99(1). 21–27. 2 indexed citations
8.
Badar, Talha, James M. Foran, David S. Viswanatha, et al.. (2023). Clinical and molecular correlates of somatic and germline <i>DDX41</i> variants in patients and families with myeloid neoplasms. Haematologica. 108(11). 3033–3043. 10 indexed citations
9.
Patnaik, Mrinal M. & Ayalew Tefferi. (2023). Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. American Journal of Hematology. 98(4). 681–689. 14 indexed citations
10.
Bezerra, Evandro D., Giacomo Coltro, Terra L. Lasho, et al.. (2020). Landscape of RAS pathway mutations in patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a study of 461 molecularly annotated patients. Leukemia. 35(2). 644–649. 7 indexed citations
11.
Tefferi, Ayalew, Jeanne Palmer, James L. Slack, et al.. (2018). Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis. American Journal of Hematology. 93(5). 649–654. 28 indexed citations
12.
Gangat, Naseema, Mrinal M. Patnaik, Kebede H. Begna, et al.. (2015). Primary Myelodysplastic Syndromes. Mayo Clinic Proceedings. 90(12). 1623–1638. 14 indexed citations
13.
Tefferi, Ayalew, Francesco Passamonti, Tiziano Barbui, et al.. (2013). Phase 3 Study Of Pomalidomide In Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis With RBC-Transfusion-Dependence. Blood. 122(21). 394–394. 24 indexed citations
14.
Tefferi, Ayalew, Rakhee Vaidya, Domenica Caramazza, et al.. (2011). Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study. Journal of Clinical Oncology. 29(10). 1356–1363. 435 indexed citations breakdown →
15.
Pardanani, Animesh, Jason Gotlib, Catriona Jamieson, et al.. (2011). Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis. Journal of Clinical Oncology. 29(7). 789–796. 310 indexed citations
16.
Gangat, Naseema, Domenica Caramazza, Rakhee Vaidya, et al.. (2010). DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. Journal of Clinical Oncology. 29(4). 392–397. 657 indexed citations breakdown →
17.
Lim, Ken-Hong, Ayalew Tefferi, Terra L. Lasho, et al.. (2009). Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 113(23). 5727–5736. 369 indexed citations
18.
Tefferi, Ayalew, Jüergen Thiele, Attilio Orazi, et al.. (2007). Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 110(4). 1092–1097. 604 indexed citations breakdown →
19.
Morice, William G., et al.. (2003). Clinical features in T‐cell vs. natural killer‐cell variants of large granular lymphocyte leukemia. European Journal Of Haematology. 71(4). 263–265. 22 indexed citations
20.
Tefferi, Ayalew & Robert L. Phyliky. (1992). A Clinical Update on Chronic Lymphocytic Leukemia. II. Critical Analysis of Current Chemotherapeutic Modalities. Mayo Clinic Proceedings. 67(5). 457–461. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Moshe Talpaz Breakdown of academic impact, for papers by Francis J. Giles Breakdown of academic impact, for papers by Andreas Hochhaus Breakdown of academic impact, for papers by Tiziano Barbui Breakdown of academic impact, for papers by Srđan Verstovšek Breakdown of academic impact, for papers by Jörge E. Cortes Breakdown of academic impact, for papers by Guillermo Garcia‐Manero Breakdown of academic impact, for papers by Michele Baccarani Breakdown of academic impact, for papers by John M. Goldman Breakdown of academic impact, for papers by Susan O’Brien
Rankless by CCL
2026